Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
B-Cell Non-Hodgkins Lymphoma
Interventions
Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
33
States / cities
Anchorage, Alaska • Clovis, California • Fullerton, California + 29 more
Conditions
B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Interventions
AZD0486 IV
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
10
States / cities
Tampa, Florida • Louisville, Kentucky • New Brunswick, New Jersey + 7 more
Conditions
Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma, Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Double-hit Lymphoma (DHL), Triple-hit Lymphoma (THL), Double-expressor Lymphoma (DEL), High-grade B-cell Lymphoma (HGBL)
Interventions
fimepinostat, Rituximab, venetoclax
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 8 more
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL), Follicular Lymphoma Grade 3B, DLBCL, DLBCL - Diffuse Large B Cell Lymphoma, DLBCL Arising From Follicular Lymphoma, DLBCL, Diffused Large B Cell Lymphoma, DLBCL NOS
Interventions
P-CD19CD20-ALLO1, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2041
U.S. locations
16
States / cities
Loma Linda, California • Los Angeles, California • Orlando, Florida + 13 more
Conditions
B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Aggressive B-Cell Non-Hodgkin Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, HGBL With MYC and BCL2 and/or BCL6 Rearrangements, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, Non-hodgkin Lymphoma,B Cell, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Epstein-Barr Virus Positive DLBCL, Nos, Follicular Lymphoma Grade 3B, DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation, High Grade B-Cell Lymphoma, Not Otherwise Specified, Follicular Lymphoma Grade 3, Marginal Zone Splenic Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinaemia
Interventions
SynKIR-310
Biological
Lead sponsor
Verismo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Atlanta, Georgia • Fairway, Kansas + 2 more